SLC5A2 and cardiovascular disorder: One such trial was the EMPA-REG OUTCOME® trial (ClinicalTrials.gov NCT01131676), in which participants with type 2 diabetes and established cardiovascular disease were randomised to receive the sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin or placebo in addition to standard of care [8].